Orchard Therapeutics plc

NasdaqCM:ORTX Stok Raporu

Piyasa değeri: US$380.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Orchard Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Orchard Therapeutics yıllık ortalama 12.3% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 36.2% annual. Gelirler yılda ortalama 57.1% oranında büyüyor .

Anahtar bilgiler

12.31%

Kazanç büyüme oranı

63.63%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.04%
Gelir büyüme oranı57.07%
Özkaynak getirisi-90.86%
Net Marj-333.90%
Son Kazanç Güncellemesi30 Sep 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Seeking Alpha • Jan 19

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Summary Orchard is trading slightly above the offered cash value at $16.44. Market ascribes $0.44 out of maximum value of $1 to CVR. This appears rich but may actually undervalue the instrument that's likely to pay out within the year. Read the full article on Seeking Alpha
Analiz Makalesi • May 09

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

With a price-to-sales (or "P/S") ratio of 4.7x Orchard Therapeutics plc ( NASDAQ:ORTX ) may be sending very bullish...
Analiz Makalesi • Mar 10

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Aug 19

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Orchard Therapeutics has become interesting after its 78% dip plus the fact that a large investment fund quadrupled its position in the stock. The company has commercialized gene therapy to combat MDL, which inflicts children. A competitive analysis reveals the strength of the U.K. based biotech. However, there are weaknesses too. This loss-making entity comes at less than $1/share and below a $100 million market cap. The therapy remains expensive. Still, at such a price and given the cash position which should last into 2024, together with the restructuring plan, this is a stock to watch for an eventual FDA approval. I became interested in ORTX after Singapore's Temasek Holdings or the country's biggest and state-owned investment fund boosted its holdings of Orchard Therapeutics Plc (ORTX) from 1 million to 4.32 million shares at around $0.58 in the second quarter of this year. They may have bought the May dip as per in the chart below, but the stock remains down, by 78% during the last year. This downtrend suggests that there is a low demand for its shares by investors, probably as profit margins are all negative and revenues for the second quarter of 2022 (Q2) have decreased to $4.4M from $5.5M on a sequential or quarter-to-quarter basis. ORTX data by YCharts However, it has been improving revenues on a year-on-year basis, which signifies some progress in its products and services. Thus, the aim of this thesis is to provide further analysis, and I start by providing an overview of Orchard's therapy. Libmeldy to Combat MDL Orchard specializes in treating metachromatic leukodystrophy ("MDL") which is characterized by mutations in the ARSA gene in turn leading to a reduction in related enzyme activity in affected children. This is a very rare genetic disease that can be fatal as it causes neurological damage and regression in cognitive (brain) development. It appears either at the late infantile or early juvenile stage, sometimes without any early clinical manifestations (symptoms) of the disease, but, in other cases, it entails cognitive decline or memory loss. In its most severe and common forms, young children quickly lose the ability to walk and interact with people around them, and many die before adolescence. MDL and Gene therapy (seekingalpha.com) As a solution, Libmeldy also referred to as OTL-200 is the first European-approved therapy for patients with early-stage MLD who meet certain clinical eligibility criteria. In Europe, it was approved by the European Medicines Agency ("EMA") in December 2020, making it the first and only approved treatment for this disease as there is no FDA-approved equivalent currently. For this matter, Orchard is working with the FDA and anticipates approval for 2023, but, it is also important to consider alternative treatments. Alternative Treatments Libmeldy is a gene-based therapy that is based first on harvesting stem cells from the blood of patients. The next step is to modify them in order to replace the defective ARSA gene I mentioned earlier with a functional version. The final step is re-introduction into the body in a single intravenous infusion. This makes it less invasive for patients compared to alternatives or more classical treatment methods for combating MLD, ranging from bone marrow, stem cell transplant, or cord blood. Also, these are still undergoing development and can only slow the progression of the disease, not stop it. In these circumstances, one would think that with the FDA approving Libmeldy in 2023 for the highly-lucrative U.S. market, Orchard would suddenly start to reap a lot of sales. However, it is more complicated. First, one problem with Libmeldy is its high cost of £2.8 million ($3.37 million), a reason why it has been labeled as the "World's most expensive drug" after it was approved by the U.K.'s NHS or National Health Service. Thus, given that its revenues are around $5 million, this means that it has only been able to sell only one to two therapies. Second, in the U.S., there are also other emerging therapies some of which are based on enzyme replacement developed by ArmaGen Technologies. There are also other gene-based therapies being developed, but most of these are in the preclinical phase. Even then, these alternative therapies are being continuously developed as they have the capability to address different forms of the disease, not necessarily in its most severe form. At the same time, the classical treatments I mentioned earlier are also being refined in order to be rendered less invasive and can for example be used to treat motor function problems for children inflicted by MDL while leaving the cognitive part to more expensive gene therapy. Therefore, while it does not face competition, Libmeldy's high price means that Orchard will not rapidly capture market share, but rather see a gradual progression in sales, somewhat similar to the progression of its quarterly income figures since 2020 unless it finds some way to reduce prices and get more volume sales. Revenue and Profitability To deliver on revenue growth for Libmeldy in Europe, Orchard has secured agreements with health authorities in Germany, Italy, and the UK, for facilitating access and reimbursement for eligible patients. Currently, patient identification is in progress, and Orchard's therapy is being assessed for reimbursement purposes in France, Spain, Belgium, Netherlands, Luxembourg, Austria, Finland, Norway, and Sweden. According to Orchard's SEC filings, this will deliver more treatments in the second half of this year compared to the first one. Thus, H2-2022 should see more revenues than the $8.84 million for the first half as per the table below. In addition to Libmeldy for MDL, Orchard has another product approved in the EU, which is Strimvelis. This is another gene therapy for the treatment of ADA-SCID, a condition whereby the body's defenses stop working because of a deficiency in the genes. Thus, out of the total revenue of $3.8 million from product sales for Q2, $0.6 million was from Strimvelis and the rest from Libmeldy. Statement of operations (www.seekingalpha.com) As for expenses, these included the cost of product sales of $1.1 million, including manufacturing and royalties paid to third parties. Additionally, R&D expenses of $22.0 million for Q2, were up only by $0.2 million for the same period in 2021 with the expectation being for costs to decline in the H2-2022 due to updating of the research portfolio and associated workforce reduction as part of a restructuration. In this respect, in addition to lab work and clinical trials, R&D also includes costs pertaining to regulatory activities in order to get Libmeldy approved in the U.S, including commercialization efforts for a potential launch in 2023. Thanks to the restructuring-related savings, the company was able to reduce operating expenses by $0.8 million in Q2, thereby reducing losses. I find this cost reduction rationale as opposed to a business-as-normal strategy to be more aligned to the current high wage inflation impacting the U.K. where Orchard is based. Such an approach allows the company to use existing cash and not increase debt levels. Valuations and Risks Another positive is collaboration revenue of $0.6 million for OTL-105 with Pharming Group N.V. (NASDAQ:PHAR) in exchange for R&D work covering stem cell gene therapy for the treatment of hereditary angioedema, a life-threatening rare disorder. This shows that Orchard has a rich pipeline with other therapies at the preclinical, clinical, and regulatory levels (diagram below) which it can monetize as part of collaborations.
Seeking Alpha • Aug 04

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Orchard Therapeutics press release (NASDAQ:ORTX): Q2 GAAP EPS of -$0.40 misses by $0.14. Revenue of $4.37M beats by $1.19M.
Seeking Alpha • Jan 20

Orchard Therapeutics: Shadow Of Former Glory

ORTX has fallen to a tenth of its mid-2020 value. No specific catastrophe, just a slow erosion of the company, has caused this. Prices are low enough to be attractive, but I will still stay neutral and wait for some derisking event before taking a call.
Seeking Alpha • Aug 16

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

ORTX is a developer of autologous gene therapies for rare diseases. Recent regulatory updates have taken the stock down. While there's a lot of promise in science, we will stay on the sidelines.
Analiz Makalesi • Jun 14

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analiz Makalesi • Feb 03

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

If you want to know who really controls Orchard Therapeutics plc ( NASDAQ:ORTX ), then you'll have to look at the...
Analiz Makalesi • Jan 08

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

How far off is Orchard Therapeutics plc ( NASDAQ:ORTX ) from its intrinsic value? Using the most recent financial data...
Analiz Makalesi • Dec 11

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

The nature of investing is that you win some, and you lose some. Anyone who held Orchard Therapeutics plc ( NASDAQ:ORTX...

Gelir ve Gider Dağılımı

Orchard Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:ORTX Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2322-73440
30 Jun 2321-85440
31 Mar 2318-124470
31 Dec 2223-151490
30 Sep 2216-179510
30 Jun 2212-168530
31 Mar 227-154530
31 Dec 212-145540
30 Sep 211-142570
30 Jun 212-12657-50
31 Mar 213-13758-25
31 Dec 203-152610
30 Sep 203-1646331
30 Jun 203-18065109
31 Mar 203-18363125
31 Dec 193-16357117
30 Sep 193-14351237
30 Jun 192-14044103
31 Mar 192-24638214
31 Dec 182-23031205
30 Sep 181-2192165
30 Jun 180-19816182
31 Mar 180-48936
31 Dec 170-40633

Kaliteli Kazançlar: ORTX şu anda kârlı değil.

Büyüyen Kar Marjı: ORTX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ORTX kârlı değildir, ancak son 5 yılda zararlarını yılda 12.3% oranında azaltmıştır.

Büyüme Hızlandırma: ORTX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ORTX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 54.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ORTX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -90.86% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/01/24 03:43
Gün Sonu Hisse Fiyatı2024/01/24 00:00
Kazançlar2023/09/30
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Orchard Therapeutics plc 9 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Charles DuncanCantor Fitzgerald & Co.
Emma NealonCantor Fitzgerald & Co.
Graig SuvannavejhGoldman Sachs